Replies to post #250454 on Biotech Values

[DewDiligence]

Re: RVNC

[Daxxify is] supposed to be best-in-class drug.

Daxxify is a best-in-class drug, and I now know this from first-hand experience (#msg-173548349). It is 17-1/2 weeks since my Daxxify treatment and I’m not seeing any movement in the treated areas. This is long past the point at which I have sought retreatment after receiving Botox.

Is it really that hard to roll out a product properly? They seems to execute well with RHA. How can they perform so messy with Daxxify?

RVNC priced RHA competitively from the outset, but they initially overpriced Daxxify to a material degree. Consequently, it will take longer than it should have taken for Daxxify to attain market share commensurate with the product’s attributes, but it will happen in due course.

Should Foley be fired?

No. When the share price takes a dive, posters on message boards like to vent, and firing the CEO is a favorite form of venting. However, replacing Foley would not speed up the market penetration of Daxxify; all it would do is further undermine the company’s stability. Foley was hired by the BoD to sell the company at the right moment, and that’s what he will eventually do, IMO.

[jbog]

Should Foley be fired?

The obvious question is what has he done right. Nada

The damage is done.